Acute leukemia is the most common pediatric malignancy. Acute myelogenous leukemia
(AML) accounts for 20% of the cases of acute leukemia among children but causes a …

Acute myelogenous, or myeloid, leukemia (AML) in children represents approx 20% of the
acute leukemias. With some minor exceptions, the biology of AML is similar in children and …

Survival rates for children with acute myeloid leukemia (AML) exceed 60% when modern,
intensified chemotherapeutic regimens and enhanced supportive care measures are …

Acute leukemia is the most common malignancy seen in childhood and is comprised mainly
by acute lymphoblastic leukemia (ALL). Acute myeloid leukemia (AML) constitutes …

Acute myelogenous leukemia (AML) accounts for approximately 20% of acute leukemias in
children. Although AML is more resistant to chemotherapy than acute lymphoblastic …

In contrast to the major advances in the treatment of childhood acute lymphoblastic leukemia
(ALL), the progress achieved in the therapy of children with acute myelogenous leukemia …

Childhood acute myeloid leukemia (AML) represents about 20% of acute childhood
leukemias. Today, the 5-year overall survival rates are close to 70%. The outcome of …

The use of intensive therapy overa brief period of time has produced dramatic improvements
in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been …

The outcome for children and adolescents with acute myelogenous leukemia (AML) has
substantially improved during the past several decades, such that nearly 50% of these …

We discuss the history and progress of treatment for acute myelogenous leukemia (AML) in
children as it has evolved over the past decade. We review the results of clinical trails for …